BioCentury
ARTICLE | Clinical News

NeuroRx's NRX-101 improves depression and suicidality in Phase II

January 11, 2019 5:27 PM UTC

NeuroRx Inc. (Wilmington, Del.) said NRX-101 improved depression and suicidality in the Phase II STABIL-B trial to treat severe bipolar depression and acute suicidal ideation and behavior. Data were presented in December at the American Congress of Neuropsychopharmacology in Hollywood, Fla.

In 15 evaluable patients, oral NRX-101 significantly reduced Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline to day 14 by 11 points vs. standard of care (SOC) lurasidone (p=0.03). NeuroRx said patients in the NRX-101 arm maintained lower MADRS scores throughout the six week-trial vs. lurasidone, but that difference was not significant (p=0.059). The company said the trial was not powered for efficacy...